Adding darolutamide (Nubeqa) to androgen deprivation therapy and docetaxel (Taxotere) can improve how long men with metastatic hormone-sensitive prostate cancer live without causing more intense side effects, results from the ARASENS trial show.
A new study reports that women are more likely than men to have severe side effects from cancer treatments such as chemotherapy, targeted therapy, and immunotherapy. The findings are based on many decades of data from 202 cancer clinical trials conducted by the NCI-sponsored SWOG Cancer Research Network. The trials involved more than 23,000 men and women.
New results from a large clinical trial show that trametinib (Mekinist) is an effective treatment for low-grade serous ovarian cancer. The findings are the first strong evidence that this rare type of ovarian cancer should be treated differently from other forms of the disease.
Dr. Nicola Mason of the University of Pennsylvania School of Veterinary Medicine describes the progress her research team has made in advancing immunotherapy research in dogs with cancer through the Pre-medical Cancer Immunotherapy Network for Canine Trials (PRECINCT) program, part of the Cancer MoonshotSM.
Clinical Trials Information for Patients and Caregivers
Designing and running a clinical trial requires the skills of many different types of experts. This page describes the typical team members involved in a clinical trial and their responsibilities.
Placebos are inactive substances or procedures that look the same, and are given the same way, as the drug or treatment being tested. Placebos are only used in cancer clinical trials when there is no standard treatment to compare an experimental therapy with or in trials that compare standard treatment plus a placebo with standard treatment plus a new treatment.
This phase 2 trial will test a combination of three types of immunotherapy for people with gastric or head and neck cancers that have either come back or not gotten better after treatment. People with cancer in the stomach or gastroesophageal junction or with a type of cancer called squamous cell carcinoma of the head and neck will be given irradiated CAR NK cells, pembrolizumab (Keytruda), and an experimental drug called N-803. Doctors want to see if giving these three different types of immunotherapy together will cause tumors to shrink or go away entirely.
This phase 1 trial will test the addition of the drug copanlisib (Aliqopa) to a combination of drugs used to treat people with certain B-cell lymphomas. Doctors want to learn if giving copanlisib with chemotherapy is safe for people with Burkitt lymphoma or diffuse large B-cell lymphoma that has come back after or not responded to treatment. They will also determine the best dose for future trials.
This phase 3 trial will test how well chemotherapy and radiation therapy work with or without the immunotherapy drug atezolizumab (Tecentriq) for treating patients with muscle-invasive bladder cancer that has not spread. Doctors want to see if adding atezolizumab to chemoradiotherapy improves bladder preservation, overall survival, and the duration of complete responses.
